Immatics N.V

NASDAQ:IMTX   10:51:15 AM EDT
8.65
-0.05 (-0.57%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)655.88M
Current PE19.31
Forward PE 12.54
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$22.43 Million
Adjusted EPS-$0.17
See more estimates
10-Day MA$8.41
50-Day MA$9.13
200-Day MA$9.61
See more pivots

Immatics N.V Stock, NASDAQ:IMTX

Paul-Ehrlich-Strasse 15, Tuebingen, Baden Wuerttemberg 72076
Germany
Phone: +49.7071.5397.0
Number of Employees: 255

Description

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.